PolyPid Ltd. (PYPD)

NCM – Real vaqt narxi. Valyuta: USD

4.56

+0.22 (5.07%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its first quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026.

28.04.2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California.

13.04.2026

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site

31.03.2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (the “FDA”) for D-PLEX₁₀₀ for the prevention of surgical site infections (“SSIs”) in patients undergoing colorectal surgery.

17.03.2026

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations

25.02.2026

PolyPid Announces Participation in Upcoming Investor Conferences

PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026.

11.02.2026

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

31.03.2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

17.03.2026

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations

11.02.2026

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀

16.12.2025

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission

PolyPid Ltd. (PYPD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PolyPid Ltd. (PYPD)

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Search stocks

PolyPid Ltd. (PYPD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PolyPid Ltd. (PYPD)

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors